Published in Int J Cancer on June 15, 1976
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci U S A (1985) 2.07
Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J Exp Med (1984) 1.94
Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus. J Virol (1992) 1.84
Susceptibility of human lymphocyte populations to infection by herpes simplex virus. Immunology (1977) 1.37
Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein. J Virol (1986) 1.29
Model for studying virus attachment: identification and quantitation of Epstein-Barr virus-binding cells by using biotinylated virus in flow cytometry. J Virol (1988) 1.29
Transfection of human lymphoblastoid cells with herpes simplex viral DNA. Proc Natl Acad Sci U S A (1979) 1.15
Bone marrow-derived lymphoid cell lines from patients with agammaglobulinemia. J Clin Invest (1978) 1.07
Immunization of mice with syngeneic Moloney lymphoma cells induces separate antibodies against virion envelope glycoprotein and virus-induced cell surface antigens. J Exp Med (1977) 0.97
The pathogenetic basis of viral tropism. Am J Pathol (1989) 0.95
Human histocompatibility determinants and virus antigens: effect of measles virus infection on HLA expression. J Exp Med (1977) 0.95
Differentiation of C3b receptors on human lymphocytes, phagocytes, erythrocytes and renal glomerulus cells by monoclonal antibodies. Immunology (1982) 0.94
Translocation of a hydrocarbon fluorescent probe between Epstein-Barr virus and lymphoid cells: an assay for early events in viral infection. Proc Natl Acad Sci U S A (1978) 0.94
Host-determined differences in expression of surface marker characteristics on human and simian lymphoblastoid cell lines transformed by Epstein-Barr virus. Proc Natl Acad Sci U S A (1977) 0.90
Rheumatoid arthritis--a virus disease? J Clin Pathol Suppl (R Coll Pathol) (1978) 0.79
Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med (1972) 24.43
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer (1973) 14.90
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med (1984) 10.66
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature (1970) 8.08
30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet (2006) 7.88
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res (1968) 7.53
The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol (1980) 6.24
Pathogenesis of chronic disease associated with persistent lymphocytic choriomeningitis viral infection. I. Relationship of antibody production to disease in neonatally infected mice. J Exp Med (1969) 6.03
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science (1998) 5.83
Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med (2001) 5.74
The role of gene dosage and genetic transpositions in carcinogenesis. Nature (1981) 5.58
Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J Virol (1984) 5.57
Molecular mimicry and autoimmune disease. Cell (1987) 5.31
Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci U S A (1974) 5.13
Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes. J Exp Med (1973) 5.03
Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine (1975) 4.68
Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci U S A (1984) 4.56
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (1995) 4.53
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology (1975) 4.48
Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J Gen Virol (1983) 4.45
Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma. Lancet (1972) 4.36
Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer (1976) 4.35
Evolution of tumours and the impact of molecular oncology. Nature (1985) 4.24
Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men. Cell (1983) 4.22
Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A (1975) 4.21
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology (1979) 4.02
Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature (1986) 4.01
Lymphocytic choriomeningitis: production of antibody by "tolerant" infected mice. Science (1967) 4.01
Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst (1970) 3.94
Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J Virol (1995) 3.90
Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science (1985) 3.69
Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science (1985) 3.68
Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A (1966) 3.56
Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J Exp Med (2000) 3.50
Suppression of malignancy by cell fusion. Nature (1969) 3.41
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J Virol (1976) 3.33
Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology (1981) 3.26
Virus-lymphocyte interactions. IV. Molecular characterization of LCMV Armstrong (CTL+) small genomic segment and that of its variant, Clone 13 (CTL-). Virology (1988) 3.22
Pathogenesis of of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. J Exp Med (1975) 3.13
Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07
Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Exp Cell Res (1975) 3.02
Relation between Epstein-Barr viral and cell membrane immunofluorescence of Burkitt tumor cells. I. Dependence of cell membrane immunofluorescence on presence of EB virus. J Exp Med (1968) 3.01
Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer (1971) 3.00
Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol (1987) 2.97
The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer (1971) 2.96
Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell (1979) 2.92
Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus. J Virol (1988) 2.82
Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations. Int J Cancer (1975) 2.81
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer (1972) 2.80
Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer (1974) 2.80
Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. J Virol (1989) 2.79
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A (1993) 2.79
Analyses of the cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein components of lymphocytic choriomeningitis virus. Virology (1988) 2.76
NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol (2000) 2.74
Organ-specific selection of viral variants during chronic infection. J Exp Med (1988) 2.71
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A (1996) 2.68
Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. Adv Cancer Res (1982) 2.68
Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A (1974) 2.66
Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer (1977) 2.66
Cellular signalling in programmed cell death (apoptosis). Immunol Today (1990) 2.64
An essential role for type 1 interferon-gamma in terminating persistent viral infection. Virology (1995) 2.60
Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature (1977) 2.58
Antibody reactions to virus-specific early antigens (EA) in patients with cytomegalovirus (CMV) infection. Clin Exp Immunol (1974) 2.57
EB virus-induced B lymphocyte cell lines producing specific antibody. Nature (1977) 2.56
How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity (1994) 2.56
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
The antibody response of mice to murine leukemia virus in spontaneous infection: absence of classical immunologic tolerance (AKR mice-complement-fixing antibodies-lymphocytic choriomeningitis virus-immunofluorescence-glomerular deposits of antigen-antibody complexes). Proc Natl Acad Sci U S A (1972) 2.54
Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol (2008) 2.53
Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus. Virology (1987) 2.53
Human lymphocyte subpopulations: classification according to surface markers and-or functional characteristics. Transplant Rev (1973) 2.53
Viral persistence in neurons explained by lack of major histocompatibility class I expression. Science (1991) 2.51
Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood (1999) 2.49
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Histocompatibility-linked genetic control of disease susceptibility. Murine lymphocytic choriomeningitis virus infection. J Exp Med (1973) 2.39
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med (1976) 2.34
Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. J Virol (1979) 2.31
Replication and persistence of measles virus in defined subpopulations of human leukocytes. J Virol (1975) 2.30
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol (1995) 2.28
Linear association between cellular DNA and Epstein-Barr virus DNA in a human lymphoblastoid cell line. Proc Natl Acad Sci U S A (1973) 2.27
Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas. J Natl Cancer Inst (1973) 2.25
The primary structure of the lymphocytic choriomeningitis virus L gene encodes a putative RNA polymerase. Virology (1989) 2.25
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature (1990) 2.23
Virus neutralization and virus-induced immune complex disease. Virus-antibody union resulting in immunoprotection or immunologic injury--two sides of the same coin. Prog Med Virol (1975) 2.23
CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J Exp Med (1996) 2.21
Tumor antigens. Annu Rev Microbiol (1966) 2.19
The action of DNA antagonists on Epstein-Barr virus (EBV)-associated early antigen (EA) in Burkitt lymphoma lines. Int J Cancer (1971) 2.18
Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol (1976) 2.18